Every material Form 8-K CNS Pharmaceuticals, Inc. has filed with the SEC since May 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
At its September 30, 2026 annual meeting, CNS Pharmaceuticals stockholders approved an amendment raising the shares authorized under the 2020 Equity Plan by 650,000, to 765,061 shares in total. Stockholders also re-elected six directors and ratified MaloneBailey, LLP as the independent auditor for 2026, and the equity plan amendment passed with 96,953 votes for and 8,128 against.
Equity plan amendment: 650,000-share increase, bringing the total authorized under the 2020 Plan to 765,061 shares; 96,953 votes for, 8,128 against, 35 abstentions, 563,072 broker non-votes.
Six directors elected to serve until the 2027 annual meeting: Faith Charles, Bettina Cockroft, Michal Fisher, Jeffrey Keyes, Rami Levin and Amy Mahery.
MaloneBailey, LLP ratified as independent registered public accounting firm for the year ending December 31, 2026.
Quorum reached with 668,188 shares, or 45.72% of the 1,461,449 shares outstanding as of the August 10, 2026 record date.
CNS Pharmaceuticals posted a June 2026 investor presentation on its website on July 2, 2026, furnished under Form 8-K Item 7.01. The deck restates its strategy to acquire clinical-stage oncology or neurology assets, funded by the $22.5 million May 2026 private placement, and says its legacy programs are being positioned for out-licensing. For shareholders, the filing details the company's plans and share count but reports no new financial results.
The May 2026 private placement closed May 5, 2026, with gross proceeds of about $22.5 million.
The placement included 650,000 common shares at $2.30 and 9,143,479 pre-funded warrants at $2.299.
As of June 30, 2026, common stock plus pre-funded warrants totaled 10,604,928 shares, with a pro forma fully diluted market capitalization of about $50.7 million.
The company says it is exploring out-licensing of its legacy berubicin program and is targeting assets with value-generating catalysts within the next 12 months.
CNS Pharmaceuticals agreed to sell 650,000 common shares and pre-funded warrants for 9,143,479 shares to institutional investors, with a closing expected May 5, 2026 and gross proceeds of approximately $22.5 million. The company plans to use the proceeds to acquire and advance new assets and for working capital, but the sale adds about 9.8 million shares that could dilute existing shareholders. The filing also reports a board resignation and the appointment of Michal Fisher as an independent director.
650,000 common shares sold at $2.30 per share; pre-funded warrants for 9,143,479 shares sold at $2.299 each
Expected closing on May 5, 2026; placement agent fee of 7.0% of gross proceeds
Company to file a resale registration statement within 15 days of closing and agreed to a 120-day limit on most new equity sales
Jerzy (George) Gumulka resigned from the Board; Michal Fisher appointed as an independent director
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CNS Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →